Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03312634 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.
A Phase 3 study, sponsored by Clementia Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 107
- Enrollment target
NCT03312634 is a Phase 3 study that has completed, run by Clementia Pharmaceuticals. The registered enrollment target is 107 participants.
The verdict
NCT03312634, a Phase 3 study, has completed, sponsored by Clementia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 107 participants
- Enrollment target
Study Summary
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by heterotopic ossification (HO) often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to ankyloses of major joints with cumulative and irreversible loss of movement and disability.
Interventions
- DRUG Palovarotene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2017-11-30 |
| Est. Completion | 2022-09-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03312634
The ClinicalTrials.gov registry entry for NCT03312634 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clementia Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Palovarotene is the first listed.
NCT03312634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03312634 about?
NCT03312634 is a clinical study titled "An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.". Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by heterotopic ossification (HO) often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to ankyloses of major joints with cumulative and irreversible loss of movem...
What is the current status of trial NCT03312634?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 107 participants. The study started on 2017-11-30. Estimated completion is 2022-09-07.
What interventions are being tested in trial NCT03312634?
The interventions under investigation include: Palovarotene (DRUG).
Who is sponsoring clinical trial NCT03312634?
This trial is sponsored by Clementia Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.